Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMP Adamis Pharmaceuticals		$1.28	$0.75 ▼ $26.18	$7.26M	1.27	811,695 shs	119,800 shs
FWP Forward Pharma A/S	$1.95	$2.17	$1.50 ▼ $6.48	$13.83M	1.38	7,484 shs	N/A
PLXP PLx Pharma		$0.00	$0.02 ▼ $0.04	$603K	3.79	12.96 million shs	3,000 shs
SMMT Summit Therapeutics	$3.54 -3.3%	$4.22	$1.30 ▼ $5.22	$2.48B	-1.21	2.26 million shs	1.25 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMP Adamis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-88.18%
FWP Forward Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%
PLXP PLx Pharma	0.00%	0.00%	0.00%	0.00%	-99.03%
SMMT Summit Therapeutics	-0.27%	-7.47%	-20.89%	+5.64%	+132.80%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	1.7126 of 5 stars	3.5	1.0	0.0	0.0	2.5	3.3	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	3.00	Buy	$8.00	125.99% Upside

Current Analyst Ratings

Latest SMMT, ADMP, FWP, and PLXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/26/2024	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMP Adamis Pharmaceuticals	$4.76M	0.00	N/A	N/A	($1.26) per share	0.00
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	$10.09 per share	N/A
PLXP PLx Pharma	$4.54M	0.00	N/A	N/A	$1.30 per share	0.00
SMMT Summit Therapeutics	$700K	3,548.60	N/A	N/A	$0.11 per share	32.18

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMP Adamis Pharmaceuticals	-$26.48M	N/A	0.00	N/A	N/A	-502.73%	-420.53%	-256.87%	N/A
FWP Forward Pharma A/S	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	-$46.13M	-$1.85	N/A	N/A	N/A	-606.91%	-291.11%	-119.43%	N/A
SMMT Summit Therapeutics	-$614.93M	-$1.53	N/A	N/A	N/A	N/A	-87.45%	-41.17%	5/9/2024 (Estimated)

Latest SMMT, ADMP, FWP, and PLXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/20/2024	Q4 2023	SMMT Summit Therapeutics	N/A	-$0.05	-$0.05	-$0.05	N/A	$0.20 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMP Adamis Pharmaceuticals	N/A	0.23	0.19
FWP Forward Pharma A/S	N/A	18.43	N/A
PLXP PLx Pharma	N/A	4.79	4.28
SMMT Summit Therapeutics	1.29	9.30	9.30

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMP Adamis Pharmaceuticals	38.55%
FWP Forward Pharma A/S	12.57%
PLXP PLx Pharma	21.19%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ADMP Adamis Pharmaceuticals	1.30%
FWP Forward Pharma A/S	71.47%
PLXP PLx Pharma	8.95%
SMMT Summit Therapeutics	83.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMP Adamis Pharmaceuticals	11	9.36 million	9.24 million	Optionable
FWP Forward Pharma A/S	4	7.09 million	2.02 million	Not Optionable
PLXP PLx Pharma	16	29.14 million	26.53 million	Not Optionable
SMMT Summit Therapeutics	105	701.70 million	114.38 million	Optionable

SMMT, ADMP, FWP, and PLXP Headlines

Source	Headline
	Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Rises By 28.6% americanbankingnews.com - April 15 at 5:40 AM
	Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.7% americanbankingnews.com - April 14 at 5:50 AM
	Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Grows By 28.6% marketbeat.com - April 13 at 7:47 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.7% marketbeat.com - April 12 at 3:59 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors finance.yahoo.com - April 11 at 5:11 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors businesswire.com - April 11 at 4:30 PM
	Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum businesswire.com - April 10 at 7:00 AM
	Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor reuters.com - April 9 at 4:33 PM
	Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer prnewswire.com - April 9 at 4:05 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Up 4.2% americanbankingnews.com - April 7 at 2:16 AM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95 marketbeat.com - April 4 at 2:02 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6% marketbeat.com - April 1 at 4:50 PM
	Summit Therapeutics CEO acquires shares worth over $411k investing.com - March 29 at 8:13 PM
	Why Summit Therapeutics Stock Crushed the Market This Week fool.com - March 29 at 5:43 PM
	Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of Stock insidertrades.com - March 29 at 7:14 AM
	Summit Therapeutics (NASDAQ:SMMT) Trading 18.9% Higher After Insider Buying Activity marketbeat.com - March 28 at 10:31 AM
	Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Buys 30,000 Shares of Stock marketbeat.com - March 27 at 9:29 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $3.28 marketbeat.com - March 26 at 12:25 PM
	Summit Therapeutics (NASDAQ:SMMT) Trading 5% Higher marketbeat.com - March 20 at 2:21 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.6% marketbeat.com - March 19 at 12:47 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $4.62 marketbeat.com - March 18 at 11:24 AM
	Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 businesswire.com - March 14 at 7:00 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT prnewswire.com - March 11 at 6:05 PM
	Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT accesswire.com - March 6 at 4:40 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamis Pharmaceuticals

NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Forward Pharma A/S

NASDAQ:FWP

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

PLx Pharma

NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Summit Therapeutics

NASDAQ:SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial